Posters

    Inflammation And Morphometric Changes In The Lungs Of Spontaneously Hypertensive Rats Following Cigarette Smoke Exposure

    Vanscheeuwijck, P.; Meurrens, K.; Van Miert, E.; Friedrichs, B.; Weiler, H.

    Conference date
    Jun 18, 2006
    Conference name
    Society of Toxicologic Pathology 25th Annual Symposium
    Link to more information
    Topic
    Summary

    Exposure to cigarette mainstream smoke (MS) induces lung inflammation, a key factor in the development of emphysema. Previously we have reported that acute and subchronic inhalation exposure of rats to diluted MS induces changes in inflammatory mediators and greater numbers of neutrophils in bronchoalveolar lavage fluid (BALF) (Vanscheeuwijck et al., 2004; Vanscheeuwijck et al., 2005; Friedrichs et al., in press). Here we report on inflammation and morphometric changes in the lungs of spontaneously hypertensive rats (SHR) following subchronic exposure to MS. The SHR strain is known to be susceptible to cigarette smoke and particle-induced cardiopulmonary alterations (Gilmour et al., 2004) and has been shown to have increased concentrations of MIP-2 and increased numbers of inflammatory cells in BALF following cigarette smoke exposure (Smith et al., 2002). We investigated pulmonary inflammation (cytokines, chemokines, and free lung cells in BALF) and morphometric changes in the lungs. 

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.